Clinical Trial Failure Risks: Sonelokimab's ongoing and future clinical trials for conditions like psoriatic arthritis (PsA) and hidradenitis suppurativa (HS) may not demonstrate sufficient efficacy or safety, leading to potential delays or discontinuation of development and a significant adverse impact on the company's prospects.

Regulatory Approval Uncertainties: Even with positive clinical trial results, Moonlake Immunotherapeutics may face challenges in obtaining timely or any regulatory approvals from health authorities like the FDA or EMA, due to various factors including safety concerns, manufacturing issues, or disagreements on trial endpoints.

Intense Market Competition: The therapeutic areas targeted by Moonlake, such as psoriatic arthritis and hidradenitis suppurativa, are highly competitive with numerous established pharmaceutical companies and emerging biotechs developing or commercializing similar or superior treatments, potentially limiting sonelokimab's market share and pricing power.